askin_heid
santen
YouTube
nidek
glaucoma_net_ru
Ассоциации
www.worldglaucoma.org
icgs2018
конгресс 2018
Основные мероприятия ассоциации офтальмологов
Beaver
ВК
icglaucoma.org
профессор
Mobile
eye5
appstore
Торика
Первая пятница декабря
camopht
АйНьюс.РФ
facebook
Флаги
oftalmolog_club
medlab
Конгресс 2014
Конгресс
Шахматы
varthamana2
bannerparasol
Новости офтальмологии
Abstract: The rebound tonometer has a unique mechanism for measuring intraocular pressure (IOP) and has become popular worldwide due to its ease of use. The most notable advantages are the lack of an air-puff and need for topical anesthesia, ease of operation and transport, and the ability to use it with children. Four rebound tonometers (Icare® TA01i, Icare PRO, Icare HOME, and Icare ic100) are currently available for clinical examination. It is important to understand the characteristics of each tonometer and select the most appropriate one because the IOP values and the purpose of measurement are different. In this review, with the goal of improving the understanding of a range of tonometers, the issues with each device are discussed.
This is your chance to submit your abstract and have it reviewed within 2 weeks after submission. A new concept to be introduced at WGC-2019: Express Abstract Review.
Ocular Therapeutix has resubmitted a new drug application to the FDA for its ocular pain treatment Dextenza, the company announced in a press release. Dextenza (dexamethasone insert 0.4 mg) is a corticosteroid intracanalicular insert placed through the punctum to deliver dexamethasone for up to 30 days.
Dry eye symptoms are experienced by many patients, especially with aging. Unfortunately, millions of patients with ocular surface disease are underdiagnosed in the United States. Being able to detect and treat dry eye disease in its early stages is becoming increasingly important. This CME activity will discuss the etiology, pathophysiology, and new methods of diagnosis and treatment for ocular surface disorders, as well as discuss clinical cases.
Are you attending WOC2018 in Barcelona? Be sure to join the WGA Symposium Glaucoma: Clinical Features and Progression on Tuesday. We look forward to meeting you there
Dr. Robert N. Weinreb Chief Editor I welcome you to the International Glaucoma Review (IGR) online. As usual, the IGR will provide you with high quality glaucoma content including the Comments in the Editor’s Selection, the Dialogue, Opinion, and news from the WGA, meeting reports, etc. With this new format, you will be able to quickly navigate the content online and obtain the information that is of interest. If desired, you also will be able to obtain more details via direct links (articles, abstracts, database, etc.).
Отличные фото с отличного конгресса Европейского глаукомного общества!
n recent years, retinal injuries caused by laser pointers have increased significantly - especially among young people. What are the preferred imaging modalities to identify these injuries? What difficulties can be expected? What role does OCT play? In his video presentation, Ethan Priel, Director of Ophthalmology Dept., MOR Institute Israel, discusses the topic comprehensively.
Программа XI открытого заседания Межнационального экспертного совета по проблемам глаукомы стран СНГ, Грузии и Балтии 30 июня 2018 года, Бишкек, Республика Кыргызстан
Abstract Purpose: Rho-associated protein kinase (ROCK) inhibitors lower intraocular pressure (IOP) by increasing aqueous outflow through the trabecular meshwork (TM). The preclinical characterization of netarsudil, a new ROCK/norepinephrine transporter (NET) inhibitor currently in clinical development, is presented herein.
The WGA aspires in becoming the most important source of education for ophthalmologists and other healthcare providers related to glaucoma. In becoming a knowledge platform, the association offers access to the Educational Portal that includes recorded sessions from past WGC’s.
A number of international studies evaluating the sensitivity of SPECTRALIS® MultiColor confocal scanning laser ophthalmoscopy versus color fundus photography were presented at the Association for Vision and Research in Ophthalmology (ARVO) 2018 conference in Honolulu, Hawaii. The studies presented at ARVO reported better sensitivity and visualization of a number of pathologies using the SPECTRALIS MultiColor Module in comparison to color fundus photography. In the figure below Amit Meshi, UCSD, San Diego, California, USA, et al. compared retinal pathology visualization and detection between the three technologies: SPECTRALIS MultiColor Module (image B), Optos P200 (image C) and Topcon TRC-50DX (image A). The authors concluded that whilst overall detection rate of retinal pathology was similar across all three devices, a larger area of macular involvement and significantly better epiretinal membrane (ERM) visualization was noted in the SPECTRALIS.
Abstract: Retinitis pigmentosa (RP) is a group of heterogeneous inherited retinal degenerative disorders characterized by progressive rod and cone dysfunction and ensuing photoreceptor loss. Many patients suffer from legal blindness by their 40s or 50s. Artificial vision is considered once patients have lost all vision to the point of bare light perception or no light perception. The Argus II retinal prosthesis system is one such artificial vision device approved for patients with RP. This review focuses on the factors important for patient selection. Careful pre-operative screening, counseling, and management of patient expectations are critical for the successful implantation and visual rehabilitation of patients with the Argus II device.
True papilledema or pseudopapilledema? Differentiating between these entities in children based on noninvasive imaging would be greatly preferable over an invasive neurological examination – the current gold standard. The authors of a recent study investigated whether the SPECTRALIS® MultiColor Module is helpful to make this distinction. Taking MultiColor images from the optic nerve head of 20 consecutive patients delivered very promising results.
With plans well underway for SOE2019 we are pleased to share our confirmed Key note Lectures which cover the breadth of Ophthalmology and are just some of the jewels in our treasure chest that is our Scientific programme. We look forward to welcoming you to the next European Congress of Ophthalmology in Nice from 13–16 June 2019. Along with a selection of the best lecturers in the world who will share every conceivable aspect of ophthalmology, our YO Committee will provide specific YO activities and sessions and the most recent state-of-art equipment and devices will be on display at the exhibition. We look forward to seeing you in Nice in 2019! Jan Tjeerd de Faber SOE President
The WGA aspires in becoming the most important source of education for ophthalmologists and other healthcare providers related to glaucoma. In becoming a knowledge platform, the association offers access to the Educational Portal that includes recorded sessions from past WGC’s. Click below to watch the recorded sessions of our past Congresses. WGC-2013 and WGC-2015 content is available for all. The sessions recorded during the 7th WGC will only be available for registered participants and will be released on a monthly basis via the different WGA media channels. WGC-2017 content is only available to WGC-2017 attendees. WGA will share several WGC-2017 sessions the upcoming year via WGA media channels. Do not miss out and subscribe to the WGA newsletter!
Many patients inquire about the use of marijuana for their uncontrolled glaucoma, especially in the setting of increased legalization in many states. In this article, Dr. Graul discusses various limitations of this Schedule I drug for long-term treatment of glaucoma, including its short duration of action, cost, ocular side effects, general health risks, and high potential for abuse. BY THOMAS A. GRAUL, MD
What has been your most successful collaboration? Without a doubt, working with Don Budenz; we’ve had enormously successful collaborations dating back more than 20 years. I owe the majority of my H-index to Don’s relentless hard work in research. We started working together in 1996 with the first use of amniotic membrane transplantation in glaucoma surgery, initially in rabbits and subsequently in a human randomized controlled trial. After that, we collaborated – or rather, Don did all the work and I helped! – in the ABC study (which we co-chaired), the Tema Eye Survey and the Tema Eye Survey II. In between, we were both investigators in the TVT and PTVT studies. Parenthetically (and outside of Ophthalmology), Don’s wife, Sue, rescued my 19-year-old son from a crack house in Chapel Hill!
his prospective, noncomparative, multicenter study was designed to evaluate the safety and efficacy of an ab interno gelatin stent (Xen Gel Stent, Allergan). Sixty-five patients aged 45 years or older with refractory open-angle glaucoma (OAG) and a history of failed filtering or cilioablative surgery and/or uncontrolled IOP (≥ 20 and ≤ 35 mm Hg) on maximum tolerated medical therapy were enrolled. The study protocol required a conjunctival peritomy to allow direct sponge application of 0.2 mg/mL mitomycin C (MMC) to the scleral bed for 2 minutes. The gelatin stent was then implanted in the sub-Tenon space in an ab interno fashion via a clear corneal incision under gonioscopic guidance, after which the conjunctiva was closed
Голосование
Что "заставляет" Вас заниматься научными исследованиями?
Популярная пресса
Фотогалерея
Интересное видео
Книги-новинки
Клуб молодых офтальмологов

МОО "Глаукомное общество"

Экспертный совет по глаукоме

Диабет. Рекомендации

Глаукома. Рекомендации ICO

Новостная лента на Twitter
Новости зарубежной офтальмологии